Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.

ABSTRACT:

Importance

Optimal chemotherapy dosing in obese patients remains uncertain, with variation in practice. Dose reduction strategies are often used to avoid chemotoxicity, but recent American Society of Clinical Oncology guidelines recommend full dose.

Objective

To evaluate the impact of body mass index (BMI) on chemotherapy dosing and of dose reduction on ovarian cancer survival.

Design, setting, and participants

Cohort study in Kaiser Permanente Northern California (KPNC) health care setting of patients with primary invasive epithelial ovarian cancers diagnosed from January 2000 through March 2013. Analyses focused on 806 patients receiving adjuvant first-line therapy of carboplatin and paclitaxel with curative intent.

Main outcomes and measures

Overall and ovar

SUBMITTER: Bandera EV 

PROVIDER: S-EPMC4567489 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature